| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188085 | SCYNEXIS | Antifungal agents |
Aug, 2030
(6 years from now) | |
| US10174074 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| US10927142 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| US11534433 | SCYNEXIS | Antifungal agents with enhanced activity in acidic pH |
Jun, 2039
(15 years from now) | |
Brexafemme is owned by Scynexis.
Brexafemme contains Ibrexafungerp Citrate.
Brexafemme has a total of 5 drug patents out of which 0 drug patents have expired.
Brexafemme was authorised for market use on 01 June, 2021.
Brexafemme is available in tablet;oral dosage forms.
Brexafemme can be used as treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatric females, treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc).
Drug patent challenges can be filed against Brexafemme from 2030-06-01.
The generics of Brexafemme are possible to be released after 10 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 1, 2026 |
| New Indication (I) | Nov 30, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 1, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 2030-06-01
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...
Dosage: TABLET;ORAL
BREXAFEMME family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic